Literature DB >> 17961261

Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia.

Gilberto Vargas-Alarcón1, José-Manuel Fragoso, David Cruz-Robles, Angélica Vargas, Alfonso Vargas, José-Ignacio Lao-Villadóniga, Ferrán García-Fructuoso, Manuel Ramos-Kuri, Fernando Hernández, Rashidi Springall, Rafael Bojalil, Maite Vallejo, Manuel Martínez-Lavín.   

Abstract

Autonomic dysfunction is frequent in patients with fibromyalgia (FM). Heart rate variability analyses have demonstrated signs of ongoing sympathetic hyperactivity. Catecholamines are sympathetic neurotransmitters. Catechol-O-methyltransferase (COMT), an enzyme, is the major catecholamine-clearing pathway. There are several single-nucleotide polymorphisms (SNPs) in the COMT gene associated with the different catecholamine-clearing abilities of the COMT enzyme. These SNPs are in linkage disequilibrium and segregate as 'haplotypes'. Healthy females with a particular COMT gene haplotype (ACCG) producing a defective enzyme are more sensitive to painful stimuli. The objective of our study was to define whether women with FM, from two different countries (Mexico and Spain), have the COMT gene haplotypes that have been previously associated with greater sensitivity to pain. All the individuals in the study were female. Fifty-seven Mexican patients and 78 Spanish patients were compared with their respective healthy control groups. All participants filled out the Fibromyalgia Impact Questionnaire (FIQ). Six COMT SNPs (rs2097903, rs6269, rs4633, rs4818, rs4680, and rs165599) were genotyped from peripheral blood DNA. In Spanish patients, there was a significant association between three SNPs (rs6269, rs4818, and rs4680) and the presence of FM when compared with healthy controls. Moreover, in Spanish patients with the 'high pain sensitivity' haplotype (ACCG), the disease, as assessed by the FIQ, was more severe. By contrast, Mexican patients displayed only a weak association between rs6269 and rs165599, and some FIQ subscales. In our group of Spanish patients, there was an association between FM and the COMT haplotype previously associated with high pain sensitivity. This association was not observed in Mexican patients. Studies with a larger sample size are needed in order to verify or amend these preliminary results.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17961261      PMCID: PMC2212567          DOI: 10.1186/ar2316

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


Introduction

Fibromyalgia (FM) is a frequent illness. Epidemiological studies from different parts of the world have shown a prevalence rate of 2% to 3% in the general population. Approximately 90% of affected individuals are female [1]. The severity of the illness diminishes the quality of life of afflicted persons [2] and imposes a heavy economic burden on society [3]. Therefore, FM can be considered a major health problem among contemporary women. Different groups of investigators have shown that autonomic dysfunction is frequent in patients with FM. Heart rate variability analyses have demonstrated signs of ongoing sympathetic hyperactivity. This hyperactivity is accompanied by a blunted sympathetic response to different stressors. It has been proposed that this autonomic dysfunction explains the multifaceted complaints of FM [4]. The defining characteristics of FM (namely, widespread pain and allodynia) could be explained by a pathogenesis known as 'sympathetically maintained pain' [5]. Naturally occurring sympathetic neurotransmitters are catecholamines known as norepinephrine, epinephrine, and dopamine. All three substances act within the central nervous system. Norepinephrine acts also in peripheral postganglionic nerve endings and exerts local effects in close proximity to the area where it is released, whereas epinephrine is the circulating hormone of the adrenal medulla and influences processes throughout the body. The major systemic transformation of catecholamines is catalyzed by the catechol-O-methyltransferase (COMT) enzyme. The COMT gene is located in region 22q11.1 to 22q11.2 of chromosome 22. There are different single-nucleotide polymorphisms (SNPs) in the COMT gene which induce important functional alterations of the enzyme. The best-studied SNP (rs4680) occurs in codon 158 with valine-to-methionine transition (Val-158-Met). The Val-158-Val genotype gives rise to an effective enzyme, whereas the Met-158-Met genotype produces a defective enzyme, which is incapable of effectively clearing catecholamines from the system [6]. Zubieta and colleagues [7] demonstrated that healthy individuals with the COMT Val-158-Val genotype are pain-resistant. The opposite occurs in people with the Met-158-Met genotype. Gursoy and colleagues [8], of Turkey, reported an association between FM and the Val-158-Met COMT polymorphism. García-Fructuoso and colleagues [9], of Spain, described that FM patients with the Met-158-Met genotype have a more severe form of the disease when compared with affected individuals with the Val-158-Val genotype. More meticulous genetic studies demonstrated that COMT functional properties are only marginally dependent on the Val-158-Met transition. There are other SNPs in the COMT gene (rs6269, rs4633, and rs4818) in linkage disequilibrium (LD) with the Val-158-Met variation. By combining these SNPs, Diatchenko and colleagues [10] were able to identify frequent COMT gene haplotypes strongly associated with sensitivity to experimental pain and induction of a more defective COMT enzyme. Healthy females with the 'high pain sensitivity haplotype' have a COMT enzyme 11 times less efficient than persons with the 'low pain sensitivity haplotype'. Diatchenko and colleagues [10] also demonstrated that COMT inhibition in rats results in a dramatic increase in sensitivity to pain. Low COMT activity may increase pain sensitivity by activating beta (2/3)-adrenergic receptors. The objective of our investigation was to define whether FM patients from two different countries (Mexico and Spain) have COMT alleles associated with increased susceptibility to pain in healthy individuals.

Materials and methods

Patients

All the subjects studied were women. The criterion for inclusion was to be diagnosed with FM as per the guidelines of the American College of Rheumatology and to be free of concurrent rheumatic disease. These patients were sourced from different private rheumatology practices in Mexico and Spain. Mexican controls were women who considered themselves to be healthy and who denied having chronic pain. Twenty-seven of them were paramedical personnel and 6 were relatives of paramedical personnel but were not related among themselves. Spanish controls were blood donors who denied having chronic pain. Patients and controls were matched by gender and age. Informed consent was obtained from all participants, and the Human Research Committee of the National Institute of Cardiology of Mexico approved the study. Both patients and controls filled out a validated Spanish translation of the Fibromyalgia Impact Questionnaire (FIQ) [11]. This is an instrument designed to numerically define the overall impact of FM across many dimensions (for example, function, pain level, fatigue, sleep disturbance, and psychological distress) [12].

Genotyping

Genomic DNA from whole blood containing EDTA (ethylenediaminetetraacetic acid) was extracted by standard techniques [13]. Six COMT SNPs (rs2097903, rs6269, rs4633, rs4818, rs4680, and rs165599) were genotyped using 5' exonuclease TaqMan assays on an ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. The National Center for Biotechnology Information (Bethesda, MD, USA) SNP database was used to assign SNP numbers.

Statistical analysis

The χ2 test was used to evaluate the Hardy-Weinberg equilibrium for each polymorphism. Statistical analysis was carried out with Stata 8.0 for Windows software (College Station, TX, USA). During the exploratory analysis, our numerical data showed a non-Gaussian distribution (Shapiro-Wilk test, p > 0.05). Therefore, Kruskal-Wallis tests were used to compare these variables. Data are presented as median and 25th and 75th percentiles. Categorical variables were analyzed with χ2 or Fisher tests as required and presented as absolute frequencies and proportions. Statistical significance was set at an alpha level of less than or equal to 0.05. The total FIQ score was correlated with genotypes and haplotypes. Mexican and Spanish groups were examined separately. Pairwise linkage disequilibrium (LD, D') estimations between polymorphisms and haplotype reconstruction were performed with Haploview version 3:32 (Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA).

Results

Table 1 shows the demographic data of the populations studied. The two groups of patients had similar age distributions and FIQ scores. However, Mexican controls had higher FIQ scores when compared with Spanish controls (p < 0.05).
Table 1

Demographic data of the studied populations

MexicanSpanish
PatientsControlsPatientsControls

Number57337880
Mean age in years (SD)45 (12)45 (12)47 (7)44 (9)
FIQ score (SD)70 (14)5.9 (6.3)a68 (11)1.6 (2.5)a

All tested individuals were women. Mexican controls had a higher Fibromyalgia Impact Questionnaire (FIQ) score when compared with Spanish controls (p < 0.05) a. SD, standard deviation.

Demographic data of the studied populations All tested individuals were women. Mexican controls had a higher Fibromyalgia Impact Questionnaire (FIQ) score when compared with Spanish controls (p < 0.05) a. SD, standard deviation. Genotype distribution of all COMT SNPs studied in both populations is shown in Table 2. The observed and expected frequencies of the different SNPs in both populations were in Hardy-Weinberg equilibrium. Statistically significant associations were found between three SNPs (rs6269, rs4818, and rs4680) and the development of FM in Spaniards. In Mexicans, the distribution of the six SNPs did not differ between patients and controls.
Table 2

Genotype distribution of the six catechol-O-methyltransferase single-nucleotide polymorphisms in patients and healthy controls from Mexico and Spain

SpanishMexican
GenotypePatientsControlsP valuePatientsControlsP value
n (%)n (%)n (%)n (%)
rs6269
 AA21 (27)14 (18)0.015a30 (53)17 (52)NS
 AG42 (54)34 (42)21 (37)13 (39)
 GG15 (19)32 (40)6 (10)3 (9)
rs4633
 CC28 (36)19 (24)NSa21 (37)17 (52)NS
 CT36 (46)37 (46)28 (49)13 (39)
 TT14 (18)24 (30)8 (14)3 (9)
rs4818
 CC19 (24)13 (16)0.00130 (53)15 (46)NS
 CG47 (60)33 (41)21 (36)12 (36)
 GG12 (16)34 (43)6 (11)6 (18)
rs4680
 AA9 (12)22 (27)0.023a2 (4)4 (12)NS
 AG40 (51)39 (49)32 (56)14 (42)
 GG29 (37)19 (24)23 (40)15 (46)
rs20907
 AA31 (40)23 (29)NSa26 (46)15 (45.5)NS
 AG34 (43)40 (50)24 (42)15 (45.5)
 GG13 (17)17 (21)7 (12)3 (9)
rs16559
 AA36 (46)33 (41)NSa12 (21)10 (30)NSa
 AG30 (39)35 (44)32 (56)15 (46)
 GG12 (15)12 (15)13 (23)8 (24)

aχ2 test; NS, not significant.

Genotype distribution of the six catechol-O-methyltransferase single-nucleotide polymorphisms in patients and healthy controls from Mexico and Spain aχ2 test; NS, not significant. Table 3 depicts the correlation between the SNPs and total FIQ score. Again, there was a strong correlation between high FIQ score and four SNP genotypes (rs6269AA, rs4633CC, rs4818CC, and rs4680GG) in Spaniards. No correlation was evident in Mexicans.
Table 3

Comparison of single-nucleotide polymorphisms and Fibromyalgia Impact Questionnaire scores in patients from Mexico and Spain

SpaniardsMexicans
Genotypes25th percentileMedian75th percentileP value25th percentileMedian75th percentileP value
rs6269
 AA75.178.682.157.767.5380.5
 AG60.667.170.10.000168.777.580.670.193
 GG51.156.356.741.0166.7779.17
rs4633
 CC73.978.786.161.471.2578.17
 CT59.862.668.50.000160.771.2982.70.785
 TT51.156.256.757.766.2185.47
rs4818
 CC75.178.182.457.764.2080.5
 GC60.265.370.20.000168.7477.581.580.054
 GG51.756.261.760.4366.3373.17
rs4680
 AA50.6252.356.157.772.9788.24
 AG59.462.168.30.000162.774.3583.600.284
 GG72.878.68559.968.7476.46

Only single-nucleotide polymorphisms with significant associations in Spaniards are shown. In Mexicans, none was associated with the Fibromyalgia Impact Questionnaire.

Comparison of single-nucleotide polymorphisms and Fibromyalgia Impact Questionnaire scores in patients from Mexico and Spain Only single-nucleotide polymorphisms with significant associations in Spaniards are shown. In Mexicans, none was associated with the Fibromyalgia Impact Questionnaire. FIQ contains several visual analogue scales. In Spaniards, there was an association between the above-mentioned SNPs and the visual analogue scale scores for pain fatigue, sleep disturbance, and morning stiffness. In Mexicans, a significant correlation was found between rs6269 and pain and fatigue as well as between rs165599 and disability and morning stiffness. LD analyses between the six SNP markers showed that four of them – rs6269, rs4633, rs4818, and rs4680 (located in the central region of the COMT gene) – had strong LDin both populations. The strongest associations were found between SNPs rs6269 with rs4680, rs6269 with rs4818, and rs4633 with rs4680 (D' = 0.986, R2 = 0.878). In light of this finding, we analyzed the most frequent haplotypes in patients and healthy controls to determine whether some of these haplotypes could be associated with the risk of developing FM among the populations in the study. There were four frequent haplotypes in Spaniards (ACCG, ATCA, GCGG, and GTGA). Haplotype distribution was different in Spanish patients versus controls (p = 0.006). Patients had higher ACCG and ATCA frequencies and a lower GTGA frequency. Mexicans had three frequent haplotypes (ACCG, ATCA, and GCGG) that were distributed similarly among patients and controls (Table 4). In Spanish patients, the ACCG haplotype was strongly associated with a high-percentile FIQ score (p = 0.0001) (Table 5).
Table 4

Haplotype frequencies in patients and healthy controls from Mexico and Spain

SpanishMexican
PatientsControlsPatientsControls

(n = 78)(n = 80)(n = 57)(n = 33)

Haplotypes
 ACCG46 (0.295)31 (0.194)33 (0.289)19 (0.287)
 ATCA34 (0.218)26 (0.162)31 (0.272)18 (0.272)
 GCGG41 (0.263)42 (0.262)23 (0.201)16 (0.242)
 GTGA24 (0.154)52 (0.325)00
 Other11 (0.070)9 (0.056)27 (0.236)13 (0.197)
Total of haplotypes15616011466
P values0.006NS

Each frequency is calculated by dividing the occurrence of a given haplotype by the total number of haplotypes in that particular group (haplotype total = number of individuals × 2). NS, not significant.

Table 5

Comparison of total Fibromyalgia Impact Questionnaire score and haplotypes using Kruskal-Wallis test

SpaniardsMexicans
25th percentileMedian75th percentileP value25th percentileMedian75th percentileP value
Haplotypes
 ACCG72.7878.0982.420.000153.5470.0577NS
 ATCA60.2162.8768.4659.668.1884.5
 GCGG60.467.1669.5660.4374.3679.17
 GTGA51.1156.156.41---

NS, not significant.

Haplotype frequencies in patients and healthy controls from Mexico and Spain Each frequency is calculated by dividing the occurrence of a given haplotype by the total number of haplotypes in that particular group (haplotype total = number of individuals × 2). NS, not significant. Comparison of total Fibromyalgia Impact Questionnaire score and haplotypes using Kruskal-Wallis test NS, not significant.

Discussion

FM strongly aggregates in families and coaggregates with mood disorders [14]. Nevertheless, previous attempts to show a specific genetic defect in FM yielded weak and/or divergent results. In a multicase family study, Yunus and colleagues [15] found a feeble association with the human leukocyte antigen (HLA) region. The reported relationship to the serotonin transporter gene (5-HTTLPR) [16] is probably linked to comorbid depression rather than to FM itself [17]. Studies on the dopamine D4 exon III repeat polymorphism yield inconsistent results [18]. In view of the sympathetic dysfunction demonstrated in FM, the COMT gene became an attractive genetic target. Exploratory studies by Gursoy and colleagues [8] and García-Fructuoso and colleagues [9] uncovered an association between the Val-158-Met (rs4680) COMT transition and FM. In contrast, Hagen and colleagues [19], using mail questionnaires, found no association between Val-158-Met transition and chronic musculoskeletal pain. Since there was no direct contact with patients, the percentage of people with musculoskeletal pain actually had FM was not established. Another report by the same group using the same method described an association between Val-158-Met polymorphism and headache [20]. In the study of Diatchenko and colleagues [10] of healthy female volunteers, SNP rs4818 accounted for 7% of pain sensitivity, SNP rs6269 for 6%, and SNP rs4680 (Val-158-Met) showed only a marginal relationship with pain sensitivity. Our results in the Spanish population are in line with these considerations. Such SNPs were associated not only with the diagnosis of FM, but also with the severity of the illness as assessed by FIQ scores. Additionally, we found SNP rs4633 to be associated with FM in Spaniards. This SNP, which represents a synonymous variation (does not produce a change in amino acid composition), was not found to be associated with pain sensitivity in the study of Diatchenko and colleagues [10]. The differences observed between Spanish and Mexican populations were an unexpected result of our study. We view two possible explanations for such a discrepancy. 1. Population differences. The Mexican population has been shown to be one of the most vigorous genetic admixtures, with genes of Caucasian, Amerindian, and African origin. A parental group represented by Spaniards has a more homogeneous background. Vargas-Alarcón and colleagues [21] analyzed the HLA allele distribution in 69 populations around the world, including Mexicans and Spaniards. Genetic distances with corresponding analyses showed important differences between these two groups [21]. Previously, it has been recognized that, in the presence of COMT alleles, there will be ethnic variations. Such variations were found not only among the general population, but also in association with disease [6]. 2. Sampling error and other stratifications. Control groups were different. Mexicans were paramedical personnel and other women who considered themselves to be healthy. Paramedical personnel are not the most representative of all people without FM in the population from which the FM cases were obtained. Mexican controls had higher FIQ scores than their blood-donor Spanish counterparts. We consider that this bias is unlikely to explain our diverging results. Even after the Mexican controls with the highest FIQ score were excluded from our calculations, differences persisted. Furthermore, although Mexican and Spanish patients had similar FIQ scores, they displayed a significantly different distribution in COMT SNP rs6269, rs16559, and rs4818. Several reports suggest that the collective grouping of SNPs in haplotypes has a stronger association with the assessed phenotype. In our study, COMT haplotype analysis showed a strong association between ACCG and ATCA and the risk of developing FM in Spanish individuals. Additionally, the ACCG haplotype was associated with a high FIQ score in Spanish patients. Previously, this haplotype has been designated as 'high pain sensitivity' due to the fact that healthy women with this particular genetic make-up are much more sensitive to painful stimuli. Our results suggest that an ACCG haplotype could be an important susceptibility marker for FM in the Spanish population.

Conclusion

Our results show an association between FM and the COMT pain sensitivity SNPs in Spaniards. By contrast, the Mexican population displayed only a weak association between the two SNPs and isolated FM symptoms. This phenomenon suggests that there are population variations in susceptibility to developing FM which are related to the COMT gene polymorphism. Studies with a larger sample size are needed in order to verify or amend these preliminary results.

Abbreviations

COMT = catechol-O-methyltransferase; FIQ = Fibromyalgia Impact Questionnaire; FM = fibromyalgia; HLA = human leukocyte antigen; LD = linkage disequilibrium; SNP = single-nucleotide polymorphism.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

GVA, JMF, DCR, MRK, and FH carried out the molecular genetic studies. FGF and JILV recruited and studied the Spanish population and purified DNA samples. RB and RS purified DNA samples from Mexico. AV and AV performed the clinical studies on Mexican participants. MV carried out the statistical analyses. MML conceived the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.
  21 in total

1.  Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits.

Authors:  Hagit Cohen; Dan Buskila; Lily Neumann; Richard P Ebstein
Journal:  Arthritis Rheum       Date:  2002-03

Review 2.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Authors:  P T Männistö; S Kaakkola
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

3.  [Relationship between COMT gene genotypes and severity of fibromyalgia].

Authors:  Ferran Josep García-Fructuoso; José Ignacio Lao-Villadóniga; Katrin Beyer; Cristina Santos
Journal:  Reumatol Clin       Date:  2008-12-10

4.  Genetic basis for individual variations in pain perception and the development of a chronic pain condition.

Authors:  Luda Diatchenko; Gary D Slade; Andrea G Nackley; Konakporn Bhalang; Asgeir Sigurdsson; Inna Belfer; David Goldman; Ke Xu; Svetlana A Shabalina; Dmitry Shagin; Mitchell B Max; Sergei S Makarov; William Maixner
Journal:  Hum Mol Genet       Date:  2004-11-10       Impact factor: 6.150

5.  COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor.

Authors:  Jon-Kar Zubieta; Mary M Heitzeg; Yolanda R Smith; Joshua A Bueller; Ke Xu; Yanjun Xu; Robert A Koeppe; Christian S Stohler; David Goldman
Journal:  Science       Date:  2003-02-21       Impact factor: 47.728

6.  The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia.

Authors:  J Rivera; T González
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

7.  The burden of musculoskeletal diseases in the general population of Spain: results from a national survey.

Authors:  L Carmona; J Ballina; R Gabriel; A Laffon
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

8.  Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome.

Authors:  Savaş Gürsoy; Emin Erdal; Hasan Herken; Ercan Madenci; Belgin Alaşehirli; Nurten Erdal
Journal:  Rheumatol Int       Date:  2002-10-22       Impact factor: 2.631

9.  Health services costs and their determinants in women with fibromyalgia.

Authors:  John R Penrod; Sasha Bernatsky; Viviane Adam; Murray Baron; Natalie Dayan; Patricia L Dobkin
Journal:  J Rheumatol       Date:  2004-07       Impact factor: 4.666

10.  The fibromyalgia impact questionnaire: development and validation.

Authors:  C S Burckhardt; S R Clark; R M Bennett
Journal:  J Rheumatol       Date:  1991-05       Impact factor: 4.666

View more
  61 in total

1.  A SCN9A gene-encoded dorsal root ganglia sodium channel polymorphism associated with severe fibromyalgia.

Authors:  Gilberto Vargas-Alarcon; Edith Alvarez-Leon; Jose-Manuel Fragoso; Angelica Vargas; Aline Martinez; Maite Vallejo; Manuel Martinez-Lavin
Journal:  BMC Musculoskelet Disord       Date:  2012-02-20       Impact factor: 2.362

2.  Association between the COMT Val158Met polymorphism and fibromyalgia susceptibility and fibromyalgia impact questionnaire score: a meta-analysis.

Authors:  Young Ho Lee; Jae-Hoon Kim; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2014-06-21       Impact factor: 2.631

Review 3.  Genetic basis of pain variability: recent advances.

Authors:  Erin E Young; William R Lariviere; Inna Belfer
Journal:  J Med Genet       Date:  2011-11-05       Impact factor: 6.318

4.  Catechol O-methyltransferase haplotype predicts immediate musculoskeletal neck pain and psychological symptoms after motor vehicle collision.

Authors:  Samuel A McLean; Luda Diatchenko; Young M Lee; Robert A Swor; Robert M Domeier; Jeffrey S Jones; Christopher W Jones; Caroline Reed; Richard E Harris; William Maixner; Daniel J Clauw; Israel Liberzon
Journal:  J Pain       Date:  2010-08-05       Impact factor: 5.820

5.  Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.

Authors:  Inna E Tchivileva; Pei Feng Lim; Shad B Smith; Gary D Slade; Luda Diatchenko; Samuel A McLean; William Maixner
Journal:  Pharmacogenet Genomics       Date:  2010-04       Impact factor: 2.089

6.  Influence of catechol-O-methyltransferase (COMT) gene polymorphisms in pain sensibility of Brazilian fibromialgia patients.

Authors:  Flávia Regina Barbosa; Josie Budag Matsuda; Mendelson Mazucato; Suzelei de Castro França; Sônia Marli Zingaretti; Lucienir Maria da Silva; Nilce Maria Martinez-Rossi; Milton Faria Júnior; Mozart Marins; Ana Lúcia Fachin
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

7.  Persistent Catechol-O-methyltransferase-dependent Pain Is Initiated by Peripheral β-Adrenergic Receptors.

Authors:  Brittney P Ciszek; Sandra C O'Buckley; Andrea G Nackley
Journal:  Anesthesiology       Date:  2016-05       Impact factor: 7.892

Review 8.  The comorbidity of insomnia, chronic pain, and depression: dopamine as a putative mechanism.

Authors:  Patrick H Finan; Michael T Smith
Journal:  Sleep Med Rev       Date:  2012-06-29       Impact factor: 11.609

Review 9.  Central pain mechanisms in the rheumatic diseases: future directions.

Authors:  Kristine Phillips; Daniel J Clauw
Journal:  Arthritis Rheum       Date:  2013-02

10.  Low enzymatic activity haplotypes of the human catechol-O-methyltransferase gene: enrichment for marker SNPs.

Authors:  Andrea G Nackley; Svetlana A Shabalina; Jason E Lambert; Mathew S Conrad; Dustin G Gibson; Alexey N Spiridonov; Sarah K Satterfield; Luda Diatchenko
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.